PMA P970037S003
- Device
- AUTODELFIA XPRESS HAFP TEST SYSTEM
- Applicant
- Revvity, Inc.
- PMA number
- P970037
- Supplement
- S003
- Product code
- LOK
- Decision date
- 2011-01-12
- Classification
- Kit, Test, Alpha-fetoprotein For Neural Tube Defects
- Generic name
- KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS
- Approval order statement
- APPROVAL TO EXTEND THE AUTODELFIA HAFP KIT ONTO THE DELFIA XPRESS INSTRUMENT. THE MODIFIED VERSION, NAMELY, DELFIA XPRESS HAFP KIT IS DESIGNED TO BE USED WITH THE 6000 DELFIA XPRESS CLINICAL RANDOM ACCESS SCREENING PLATFORM. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME DELFIA XPRESS HAFP KIT AND IS INDICATED FOR `THE QUANTITATIVE DETERMINATION OF HUMAN ALPHA-FETOPROTEIN (AFP) IN MATERNAL SERUM AND AMNIOTIC FLUID OBTAINED BETWEEN THE 15TH AND 20TH WEEKS OF GESTATION. THE ASSAY IS TO BE PERFORMED ON THE 6000 DELFIA XPRESS CLINICAL RANDOM ACCESS SCREENING PLATFORM AND IS INTENDED FOR USE ONLY IN CONJUNCTION WITH OTHER DIAGNOSTIC TOOLS SUCH AS ULTRASOUND AND AMNIOGRAPHY AS AN AID IN THE DETECTION OF OPEN NEURAL TUBE DEFECTS (ONTDS).
Current openFDA PMA Record#
- Device
- AUTODELFIA XPRESS HAFP TEST SYSTEM
- Applicant
- Revvity, Inc.
- PMA number
- P970037
- Supplement
- S003
- Product code
- LOK
- Generic name
- KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS
- Decision date
- 2011-01-12
- Decision code
- APPR
- Date received
- 2010-03-01
- Supplement type
- Normal 180 Day Track
- Supplement reason
- Change Design/Components/Specifications/Material
- Approval order statement
- APPROVAL TO EXTEND THE AUTODELFIA HAFP KIT ONTO THE DELFIA XPRESS INSTRUMENT. THE MODIFIED VERSION, NAMELY, DELFIA XPRESS HAFP KIT IS DESIGNED TO BE USED WITH THE 6000 DELFIA XPRESS CLINICAL RANDOM ACCESS SCREENING PLATFORM. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME DELFIA XPRESS HAFP KIT AND IS INDICATED FOR `THE QUANTITATIVE DETERMINATION OF HUMAN ALPHA-FETOPROTEIN (AFP) IN MATERNAL SERUM AND AMNIOTIC FLUID OBTAINED BETWEEN THE 15TH AND 20TH WEEKS OF GESTATION. THE ASSAY IS TO BE PERFORMED ON THE 6000 DELFIA XPRESS CLINICAL RANDOM ACCESS SCREENING PLATFORM AND IS INTENDED FOR USE ONLY IN CONJUNCTION WITH OTHER DIAGNOSTIC TOOLS SUCH AS ULTRASOUND AND AMNIOGRAPHY AS AN AID IN THE DETECTION OF OPEN NEURAL TUBE DEFECTS (ONTDS).